肿瘤治疗始终面临着诸多挑战，提高治疗的特异性、疗效并降低副作用是关键目标。免疫疗法作为一种新兴的治疗手段，在过去几十年中得到了广泛研究。嵌合抗原受体 T（CAR-T）细胞疗法在血液系统恶性肿瘤治疗中取得了显著成效，但存在生产成本高昂、制备过程复杂以及潜在慢性毒副作用等问题。

Notably, IFT20 clusters with TCRs at the immune synapse and associates with the ζ- and ɛ-chains of CD3 in response to TCR engagement. TCR–CD3 complex assembly is initiated in the endoplasmic ...

2024年，两款TCE药物全球首次获得批准上市。安进开发的DLL3/CD3 TCE在5月获美国FDA加速批准，用于一线治疗广泛期小细胞肺癌成人患者，为首款用于治疗实体瘤的双特异性TCE。再生元开发的CD20/CD3靶向TCE Odronextamab于8月份获EMA批准上市，首次获批准用于治疗复发或难治性（R/R）滤泡性淋巴瘤或R/R弥漫性大B细胞淋巴瘤成年患者。

T cell activation requires a T cell receptor (TCR) to recognize its cognate peptide in the context of an MHC molecule. In addition, the association of CD3 with the TCR–peptide–MHC complex ...

智通财经APP获悉，中国国家药监局药品审评中心(CDE)官网最新公示，诺华(NVS.US)申报的1类新药PIT565获得一项新的临床试验默示许可，拟开发治疗系统性红斑狼疮(SLE)。公开资料显示，这是诺华在研的一款抗CD3/CD19/CD2的三特异性抗体，此前已经在中国获批针对B细胞恶性肿瘤的IND。目前，PIT565正处于国际多中心1期研究阶段， ...

Image Credit: ACROBiosystems CD3 molecules tend to bind to TCR non-covalently to develop a TCR/CD3 receptor complex on the T-cell’s surface. There are four subtypes of CD3 — CD3ε, CD3δ ...

11,12 (8) Synthetic TCR antigen receptor/HLA-independent TCR (STAR/HIT) constructs retain the full complex of CD3 signaling but also have high antigen sensitivity via the fusion of an antibody binding ...

that consists of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes – as a treatment for unresectable or metastatic uveal melanoma.